Publications by authors named "Marco Biancotto"
Objective: Cost-effectiveness of surveillance for branch-duct intraductal papillary mucinous neoplasms (BD-IPMNs) is debated. We combined different categories of risks of IPMN progression and of IPMN-unrelated mortality to improve surveillance strategies.
Design: Retrospective analysis of 926 presumed BD-IPMNs lacking worrisome features (WFs)/high-risk stigmata (HRS) under surveillance.
Background: Mucinous Cystic Neoplasms (MCN) of the pancreas are premalignant cysts for which current guidelines support pancreatic resection. The primary aim of this systematic review and meta-analysis is to define the pooled rate of malignancy for MCN.
Methods: A systematic review of eligible studies published between 2000 and 2021 was performed on PubMed and Embase.
Article Synopsis
- Some doctors use an app called iCyst to learn about guidelines for treating pancreatic cysts.
- The study looked at how many doctors used the app and which guidelines they chose over a year.
- Most doctors preferred European guidelines, and the app could help in future research about treating pancreatic cystic problems.
Importance: The progression of intraductal papillary mucinous neoplasms (IPMNs) of the pancreas to malignant disease is still poorly understood. Observational and surgical series have failed to provide comprehensive information.
Objective: To identify dynamic variables associated with the development of malignant neoplasms by combining pathological features with data from preoperative repeated observations.
Objective: Our aim is to provide a real-life picture of serous cystic neoplasms (SCNs) management once a presumptive diagnosis is made.
Summary Of Background Data: SCNs of the pancreas are invariably benign entities. While consensus about their management is lacking, surgical resection still plays a role.
Objectives: The management of small and incidental branch duct intraductal papillary mucinous neoplasms (BD-IPMNs) still is of concern. The aim is assessing the safety of a surveillance protocol through the evaluation of their progression to malignancy.
Methods: All presumed BD-IPMNs observed from 2000 to 2016 were included.